Cellectis is the pioneering gene editing company, deploying core proprietary technologies to develop off-the-shelf immunotherapies to target and eradicate cancer cells.

Gene editing

The principle of gene editing is very simple: in the same way that spell check identifies and corrects errors in a word or grammar errors in a sentence, gene editing can be used to precisely edit the genetic code within an individual's DNA.
Learn more

Editing Life

Faces Behind the Gene Editing Revolution

Learn more


Our product candidates, based on gene-edited T-cells that express Chimeric Antigen Receptors, or CARs, seek to harness the power of the immune system to target cancers.
Learn more